Vaxart, Inc. (VXRT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vaxart, Inc.
Address
170 Harbor Way
South San Francisco, CA 94080
United States of America (the)
Phone
650 550 3500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
105
First IPO Date
December 11, 1981
Key Executives
| Name | Title | Pay | Year Born |
| Steven Lo | President, Chief Executive Officer & Director | 1.07M | 1967 |
| Sean N. Tucker | Senior Vice President & Chief Scientific Officer | 657,022 | 1968 |
| James F. Cummings | Chief Medical Officer | 744,272 | 1966 |
| Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management | 0 | N/A |
| Rajesh Kapoor | Senior Vice President of Quality | 0 | N/A |
| Edward Berg | Senior Vice President & General Counsel | 0 | 1964 |
| Jeroen Grasman | Chief Financial Officer, Principal Accounting Officer & Principal Financial Officer | 0 | 1970 |
| Laurie Hastings | Senior Vice President of Human Resources | 0 | N/A |
Description
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
